198 related articles for article (PubMed ID: 33239228)
1. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.
Huang Z; He J; Su J; Ou Z; Liu G; Fu R; Shou Q; Zheng M; Group T; Luxembourg A; Liao X; Zhang J
Vaccine; 2021 Jan; 39(4):760-766. PubMed ID: 33239228
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.
Lv H; Wang S; Liang Z; Yu W; Yan C; Chen Y; Hu X; Fu R; Zheng M; Group T; Luxembourg A; Liao X; Chen Z
Vaccine; 2022 May; 40(23):3263-3271. PubMed ID: 35487814
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
Garland SM; Anagani M; Bhatla N; Chatterjee S; Lalwani S; Ross C; Group T; Lin J; Luxembourg A; Walia A; Tu Y
Hum Vaccin Immunother; 2022 Nov; 18(6):2105067. PubMed ID: 35997582
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial.
Thiem VD; Quang ND; Tuan NH; Cheon K; Gallagher N; Luxembourg A; Group T; Badshah C
Hum Vaccin Immunother; 2021 Jul; 17(7):1980-1985. PubMed ID: 33844623
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
Mugo N; Ansah NA; Marino D; Saah A; Garner EI
Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.
Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A
Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325
[TBL] [Abstract][Full Text] [Related]
8. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up.
Chen W; Zhao Y; Xie X; Liu J; Li J; Zhao C; Wang S; Liao X; Shou Q; Zheng M; Saah AJ; Wei L; Qiao Y
Vaccine; 2019 Feb; 37(6):889-897. PubMed ID: 30638797
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.
Joura EA; Ulied A; Vandermeulen C; Rua Figueroa M; Seppä I; Hernandez Aguado JJ; Ahonen A; Reich O; Virta M; Perino A; Peris Tuser M; Peters K; Origoni M; Raspagliesi F; Tjalma WAA; Tummers P; Woelber L; Nieminen P; van Damme P; Sehouli J; Fiol Ruiz G; Brucker S; Fehm T; Cheon K; Rawat S; Luxembourg A; Wittke F
Vaccine; 2021 May; 39(20):2800-2809. PubMed ID: 33676783
[TBL] [Abstract][Full Text] [Related]
10. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
[TBL] [Abstract][Full Text] [Related]
11. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years.
Maldonado I; Plata M; Gonzalez M; Correa A; Nossa C; Giuliano AR; Joura EA; Ferenczy A; Ronnett BM; Stoler MH; Jin Zhou H; Joshi A; Das R; Bautista O; Group T; Luxembourg A; Saah A; Buchwald UK
Hum Vaccin Immunother; 2022 Nov; 18(5):2078626. PubMed ID: 35853188
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls.
Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M
Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women.
Sakamoto M; Miyagi E; Sumi Y; Aisaka K; Kuno N; Nagano H; Asahara S; Han SR; Wakana A; Murata S; Sawata M; Tanaka Y
J Infect Chemother; 2019 Jul; 25(7):520-525. PubMed ID: 30879979
[TBL] [Abstract][Full Text] [Related]
15. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J
Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
Mikamo H; Yamagishi Y; Murata S; Yokokawa R; Han SR; Wakana A; Sawata M; Tanaka Y
Vaccine; 2019 Mar; 37(12):1651-1658. PubMed ID: 30797638
[TBL] [Abstract][Full Text] [Related]
17. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
Gilca V; Sauvageau C; Boulianne N; De Serres G; Crajden M; Ouakki M; Trevisan A; Dionne M
Hum Vaccin Immunother; 2015; 11(3):732-8. PubMed ID: 25714044
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial.
Donken R; Dobson SRM; Marty KD; Cook D; Sauvageau C; Gilca V; Dionne M; McNeil S; Krajden M; Money D; Kellner J; Scheifele DW; Kollmann T; Bettinger JA; Liu S; Singer J; Naus M; Sadarangani M; Ogilvie GS
Clin Infect Dis; 2020 Aug; 71(4):1022-1029. PubMed ID: 31617568
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial.
Landier W; Bhatia S; Wong FL; York JM; Flynn JS; Henneberg HM; Singh P; Adams K; Wasilewski-Masker K; Cherven B; Jasty-Rao R; Leonard M; Connelly JA; Armenian SH; Robison LL; Giuliano AR; Hudson MM; Klosky JL
Lancet Child Adolesc Health; 2022 Jan; 6(1):38-48. PubMed ID: 34767765
[TBL] [Abstract][Full Text] [Related]
20. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.
Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A
Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
